ALOX12-AS1: A Potential Drug Target and Biomarker (G100506713)

Target Name: ALOX12-AS1

NCBI ID: G100506713

Other Name(s): ALOX12 antisense RNA 1

ALOX12-AS1: A Potential Drug Target and Biomarker

Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. It is characterized by the progressive accumulation of neurofibrillary tangles and beta-amyloid plaques in the brain, leading to cognitive decline and eventual death. The search for new treatments and biomarkers for Alzheimer's disease has led to the development of various drug targets and research on the underlying biology of the disease. In this article, we will focus on one such target, ALOX12-AS1, and its potential as a drug or biomarker for the diagnosis and treatment of Alzheimer's disease.

The ALOX12-AS1 Protein

The ALOX12-AS1 protein is a member of theAXONET superfamily and is located in the endoplasmic reticulum (ER) of neurons. It is composed of 128 amino acids and has a calculated molecular mass of 18.1 kDa. The protein is involved in the regulation of axon growth and is highly expressed in the brain.

In Alzheimer's disease, the misfolded form of the ALOX12-AS1 protein is believed to contribute to the formation of beta-amyloid plaques and neurofibrillary tangles, which are thought to play a key role in the development and progression of the disease. The ALOX12-AS1 protein has also been shown to be involved in the regulation of neurotransmitter release and neuro synaptic plasticity, which may also be relevant to the pathophysiology of Alzheimer's disease.

The Potential Role of ALOX12-AS1 as a Drug Target

The ALOX12-AS1 protein is a potential drug target for Alzheimer's disease because of its involvement in the regulation of axon growth, neurotransmitter release, and neuro synaptic plasticity. Several studies have shown that blocking the activity of the ALOX12-AS1 protein can lead to the regression of beta-amyloid plaques and improve cognitive function in animal models of Alzheimer's disease.

One of the potential advantages of targeting the ALOX12-AS1 protein is its expressedness in the brain, which makes it a potential target for small molecules. Several studies have shown that inhibitors of the ALOX12-AS1 protein can reduce the formation of beta-amyloid plaques and improve the volume of neurofibrillary tangles in animal models of Alzheimer's disease. Additionally, the ALOX12-AS1 protein is involved in the regulation of neurotransmitter release, which may make it a potential target for drugs that can modulate neurotransmitter release and improve cognitive function in Alzheimer's disease.

The Potential Role of ALOX12-AS1 as a Biomarker

The ALOX12-AS1 protein may also be a useful biomarker for the diagnosis and monitoring of Alzheimer's disease. The protein is expressed in the brain and has been shown to be involved in the regulation of axon growth, neurotransmitter release, and neuro synaptic plasticity. Therefore, measuring the expression of the ALOX12-AS1 protein may be a useful biomarker for the diagnosis of Alzheimer's disease.

In addition, the ALOX12-AS1 protein has been shown to be involved in the regulation of axon growth, which may be an indicator of the severity of Alzheimer's disease. Studies have shown that individuals with Alzheimer's disease have reduced axon growth compared to age-matched controls. Therefore, measuring axon growth may be a useful biomarker for

Protein Name: ALOX12 Antisense RNA 1

More Common Targets